ClinicalTrials.gg
Not yet recruitingNCT07849998Updated Oct 5, 2026

Genotype and Phenotype in Pediatric Familial Mediterranean Fever

An observational study in Familial Mediterranean Fever, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Assiut University · Observational

How we know

Updated Oct 5, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
84
Ages
1 Month to 18 Years
Sex
All
01

Study summary

This cross-sectional study aims to assess the spectrum of MEFV gene mutations and their relation to clinical manifestations and disease severity in children with Familial Mediterranean Fever attending Assiut University Children Hospital.

Read the detailed description

Familial Mediterranean Fever is a common autoinflammatory disease in children of Mediterranean origin. This observational study will include pediatric patients with a clinical diagnosis of FMF according to Tel-Hashomer or Yalcinkaya-Ozen criteria who have available MEFV genetic testing.

Clinical features, disease severity (ISSF score), and genetic variants will be recorded and analyzed in a single assessment.

02

Conditions studied

  • Familial Mediterranean Fever

Keywords

  • Familial Mediterranean Fever
  • MEFV gene
  • Genotype
  • Phenotype
  • Assiut
03

In context

Familial Mediterranean Fever

61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.

This study's planned enrollment of 84 is close to the median of 89 across 30 observational studies indexed under Familial Mediterranean Fever.

Browse Familial Mediterranean Fever studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients with Familial Mediterranean Fever attending the Pediatric Allergy, Immunology and Rheumatology Unit at Assiut University Children Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Age less than 18 years
  • Clinical diagnosis of FMF according to Tel-Hashomer or Yalcinkaya-Ozen criteria
  • Availability of molecular genetic testing for MEFV gene mutations
  • Disease duration of at least 6 months
  • Written from legal caregivers

Exclusion criteria

Exclusion Criteria:

  • - Other autoinflammatory diseases (CAPS, TRAPS, hyper-IgD syndrome)
  • diseases (systemic lupus erythematosus, juvenile idiopathic arthritis)
  • Incomplete genetic workup
  • Pre-existing chronic kidney disease or amyloidosis attributable to a cause other than FMF
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
84 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Pediatric FMF Patients

    Children with confirmed clinical diagnosis of Familial Mediterranean Fever who have available MEFV genetic results and will undergo clinical and severity assessment.

06

What researchers measure

Primary outcomes

  1. Frequency of MEFV gene mutations

    Proportion of children with MEFV gene mutations among the studied pediatric FMF patients.

    Time frame: Baseline

  2. Mean ISSF disease severity score

    Mean International Severity Scoring System for Familial Mediterranean Fever (ISSF) score. The score ranges from 0 to 14, with higher scores indicating more severe disease.

    Time frame: Baseline

Secondary outcomes

  1. Mean age at symptom onset

    Mean age at symptom onset of FMF in years..

    Time frame: Baseline

  2. Mean age at diagnosis

    Mean age at diagnosis of FMF in years.

    Time frame: Baseline

  3. Frequency of fever attacks

    Proportion of children presenting with recurrent fever attacks.

    Time frame: Baseline

  4. Frequency of abdominal pain

    Proportion of children presenting with abdominal pain during attacks.

    Time frame: Baseline

  5. Frequency of arthritis or arthralgia

    Proportion of children presenting with arthritis or arthralgia during attacks.

    Time frame: Baseline

  6. Frequency of chest pain

    Proportion of children presenting with chest pain during attacks

    Time frame: Baseline

  7. Mean colchicine dose

    Mean daily colchicine dose in milligrams.

    Time frame: Baseline

  8. Proportion of patients with complete colchicine response

    Proportion of patients showing complete response to colchicine therapy.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Feb 20, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionMean ISSF disease severity score: how it is measured was reworded
Oct 5, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 5, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionMean ISSF disease severity score: how it is measured was reworded
    + 1 other change: responsible party
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849998
Lead sponsor
Assiut University
Responsible party
Rana Ashraf Ahmed Hussein (Principal Investigator, Assiut University) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Rana A Ahmed, Resident
Contact
Rana.18313220@med.aun.edu.eg
01011062546
Maher M Ahmed, prof
study chair · Pediatrics Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion